When is a sentinel node biopsy indicated for patients with primary melanoma? Comment on the ‘Australian guidelines for the management of cutaneous melanoma’
Michael Sladden
Department of Medicine, University of Tasmania, Launceston, Tasmania, Australia
All four authors made identical contributions to this article.Search for more papers by this authorSamuel Zagarella
Department of Dermatology, University of Sydney Medical School, Sydney, New South Wales, Australia
All four authors made identical contributions to this article.Search for more papers by this authorCatalin Popescu
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
All four authors made identical contributions to this article.Search for more papers by this authorMichael Bigby
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
All four authors made identical contributions to this article.Search for more papers by this authorMichael Sladden
Department of Medicine, University of Tasmania, Launceston, Tasmania, Australia
All four authors made identical contributions to this article.Search for more papers by this authorSamuel Zagarella
Department of Dermatology, University of Sydney Medical School, Sydney, New South Wales, Australia
All four authors made identical contributions to this article.Search for more papers by this authorCatalin Popescu
Department of Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
All four authors made identical contributions to this article.Search for more papers by this authorMichael Bigby
Department of Dermatology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
All four authors made identical contributions to this article.Search for more papers by this author
References
- 1Gyorki DE, Barbour A, Hanikeri M et al. When is a sentinel node biopsy indicated for patients with primary melanoma? An update of the ‘Australian guidelines for the management of cutaneous melanoma’. Australas. J. Dermatol. 2017; 58: 274–7.
- 2Zagarella S, Lee S, Heenan P. Sentinel lymph node biopsy status is not the most powerful predictor of prognosis in cutaneous melanoma. Australas. J. Dermatol. 2017; 58: 256–8.
- 3Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 2006; 355: 1307–17.
- 4Morton DL, Thompson JF, Cochran AJ et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N. Engl. J. Med. 2014; 370: 599–609.
- 5Check W. Sentinel lymph node dissection for melanoma: is the standard of care ahead of the evidence?. Available from URL: http://www.captodayonline.com/Archives/1211/1211c_sln.html. (Accessed 16 Sep 2017.)
- 6Grob J-J. How long will sentinel node biopsy remain standard in melanoma? Melanoma Letter 2015; 33: 6–8.
- 7Sladden M, Zagarella S, Popescu C et al. No survival benefit for melanoma patients undergoing sentinel node biopsy: critical appraisal of the multicenter selective lymphadenectomy trial-1 final report. Br. J. Dermatol. 2015; 172: 566–71.
- 8 NICE Guidance. Melanoma: assessment and management. Available from URL: https://www.nice.org.uk/guidance/ng14/chapter/1-recommendations. (Accessed 16 Sep 2017.)
- 9Faries MB, Thompson JF, Cochran AJ et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N. Engl. J. Med. 2017; 376: 2211–22.
- 10Long GV, Hauschild A, Santinami M et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 2017; 377: 1813–23.
Citing Literature
